Exchange: NYSE·Updated 03:53 PM EDT
News
all
press releases
Can Eliquis Cushion Bristol Myers' Legacy Portfolio Erosion?
BMY's legacy portfolio faces generic pressure, but stronger Eliquis sales prompt a brighter 2026 revenue outlook.
Zacks
More News
Moderna Stock Cools Off After-Hours, Following Massive 177% Cancer Vaccine Rally Merck, Pfizer and BioNTech Among mRNA Names Trending Tonight
Healthcare stocks saw mixed after-hours moves, with Moderna and Merck cooling after explosive gains on positive cancer trial results.read more...
Benzinga
Merck Just Raised the Stakes for Pfizer's Cancer Vaccine Ambitions
Merck's deeper push into personalized cancer vaccines raises the competitive bar for Pfizer, BioNTech in biotech's fastest-growing race.read more...
Benzinga
Pfizer Stock Rises Wednesday: What's Going On?
Pfizer Inc (NYSE:PFE) shares are trading higher Wednesday, moving in sympathy with mRNA cancer vaccine-related companies after Merck & Co Inc?(NYSE:MRK) and Moderna Inc?(NASDAQ:MRNA) announced that their combination therapy of intismeran autogene and Keytruda showed positive recurrence-free...
Benzinga
OPK Raises $125 Million Against Royalties: What Investors Should Know
OPKO Health secured $125 million in royalty-backed financing, adding non-dilutive capital while retaining long-term exposure to mazdutide growth in China.
Zacks
Is OPK Worth Buying as Valuation Meets Improving Business Trends?
OPKO Health pairs a discounted forward sales multiple with narrowing losses and partnership support, but early-stage clinical risk keeps the investment case balanced.
Zacks
OPK Climbs 12.4% in the Past Month: Can the Stock Rally Keep Going?
OPKO Health's 12.4% monthly gain is backed by narrower losses and better margins, though profitability and clinical execution remain key risks.
Zacks
Pfizer's Obesity Push: Can Berobenatide Take Market Share?
PFE aims to break into the obesity market with berobenatide, a potential monthly treatment designed to compete with leading GLP-1 therapies.
Zacks
Insider Watch: 3 CEOs Betting Millions on Their Own Stocks
Several stocks have recently seen notable insider buys from CEOs, including a $10 million dollar bet from a semiconductor favorite.
Zacks
J&J's New Growth Powerhouses: Immunology and Neuroscience
J&J's immunology and neuroscience businesses are emerging as key growth engines, with new drugs helping to offset Stelara's loss of exclusivity.
Zacks

Advertisement|Remove ads.